Kindeva Celebrates 70 Years of pMDI Innovation
Kindeva, a leader in contract development and manufacturing, marked a significant milestone in respiratory care as it celebrated 70 years since the introduction of the pressurized metered dose inhaler (pMDI).
A Revolutionary Advancement in Healthcare
The pMDI, which was first introduced to the market in 1956, revolutionized the way respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD) are treated. Before its invention, the only option available was the cumbersome squeeze-bulb nebulizer. The pMDI offered a more portable and efficient alternative, transforming how patients accessed their medications.
Kindeva's celebration coincided with the induction of George Maison, Irving Porush, and Charles Thiele, the innovators behind the pMDI, into the National Inventors Hall of Fame. This prestigious recognition honors those whose contributions have significantly enhanced the quality of life for many, recognizing their place among luminaries like Frederick Banting and Charles Best, known for isolating insulin, and Emmanuelle Charpentier, co-developer of CRISPR technology.
Honoring Innovation
Jeremy Tidmarsh, the Vice President of Kindeva's MDI business unit, expressed pride in the achievements of the inductees: "From its very beginnings, Kindeva set out to discover and manufacture life-saving treatments that make a real impact on patient lives. It is a great honor for our former colleagues George, Irving, and Charles to be nominated alongside such inspiring figures in American history."
The panel that selected the inductees comprised experts in science, technology, engineering, and patent-related industries. They recognized the inventors’ dedication to developing solutions that improved societal well-being through their innovative spirit and hard work.
Continuing a Legacy of Innovation
Since its inception, the pMDI has become the most widely accepted treatment for asthma, significantly decreasing asthma-related mortality rates since the 1980s. This device has played an essential role in managing respiratory health for millions worldwide.
Kindeva remains committed to advancing pMDI technology and has recently invested in a new center of excellence located in Loughborough, UK, launched in September 2025. This facility will enhance the company’s capabilities in developing next-generation inhalation devices using environmentally sustainable propellants.
Tidmarsh noted, "While we celebrate this landmark achievement, our focus is on the future, delivering innovative propellants that will not only improve patients' lives but also help manufacturers meet global sustainability standards."
Looking Ahead
Kindeva’s tagline, "Manufacturing More Tomorrows™," encapsulates its mission to provide innovative drug delivery solutions that meet the evolving healthcare needs of today's society. The company’s global footprint, consisting of ten manufacturing and research and development sites, enables it to deliver exceptional quality and capability in drug production, including state-of-the-art aseptic fill finish capacity.
Kindeva's advancements in drug delivery technology extend beyond respiratory applications, incorporating platforms for injectable, pulmonary, nasal, and dermal therapies. As the company continues to innovate at the intersection of health technology and sustainability, it remains dedicated to making a lasting positive impact on global health.
For more information on Kindeva’s services and innovations, visit their official website at
Kindeva.
About the National Inventors Hall of Fame
The National Inventors Hall of Fame is a nonprofit organization established to honor inventors and promote innovation. It encourages creativity and entrepreneurship through educational programming focused on science, technology, engineering, and mathematics (STEM). Founded in partnership with the United States Patent and Trademark Office, it helps inspire future generations of innovators. To learn more, or to nominate an inventor for induction, please visit
invent.org.